- Home
- DSP vs KMDA Comparison
DSP vs KMDA Comparison
Compare DSP & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- KMDA
- Stock Information
- Founded
- DSP 1999
- KMDA 1990
- Country
- DSP United States
- KMDA Israel
- Employees
- DSP N/A
- KMDA N/A
- Industry
- DSP EDP Services
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- KMDA Health Care
- Exchange
- DSP Nasdaq
- KMDA Nasdaq
- Market Cap
- DSP 330.3M
- KMDA 349.6M
- IPO Year
- DSP 2021
- KMDA N/A
- Fundamental
- Price
- DSP $20.74
- KMDA $5.87
- Analyst Decision
- DSP Strong Buy
- KMDA Strong Buy
- Analyst Count
- DSP 7
- KMDA 2
- Target Price
- DSP $17.71
- KMDA $14.50
- AVG Volume (30 Days)
- DSP 266.9K
- KMDA 30.2K
- Earning Date
- DSP 11-12-2024
- KMDA 11-13-2024
- Dividend Yield
- DSP N/A
- KMDA N/A
- EPS Growth
- DSP N/A
- KMDA 124.29
- EPS
- DSP 0.08
- KMDA 0.27
- Revenue
- DSP $263,587,000.00
- KMDA $158,380,000.00
- Revenue This Year
- DSP $28.26
- KMDA $15.38
- Revenue Next Year
- DSP $12.19
- KMDA $6.18
- P/E Ratio
- DSP $272.33
- KMDA $21.16
- Revenue Growth
- DSP 23.73
- KMDA 4.52
- 52 Week Low
- DSP $6.31
- KMDA $4.74
- 52 Week High
- DSP $21.74
- KMDA $6.53
- Technical
- Relative Strength Index (RSI)
- DSP 71.06
- KMDA 52.31
- Support Level
- DSP $19.82
- KMDA $5.71
- Resistance Level
- DSP $21.25
- KMDA $5.90
- Average True Range (ATR)
- DSP 1.09
- KMDA 0.16
- MACD
- DSP -0.19
- KMDA -0.03
- Stochastic Oscillator
- DSP 71.76
- KMDA 40.35
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.